期刊论文A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis复制

DOI:复制

文献链接:复制

其他信息:

F Huang, J Zhang, JL Huang, DH Wu, ZG Li…
Zhonghua nei ke za …, 2010
europepmc.org
Objective To evaluate the short-term efficacy and safety of etanercept treatment in Chinese patients with active ankylosing spondylitis (AS). Methods This was a 12-week multicenter, double-blind, placebo-controlled, randomized phase III clinical study. The first part was a 6-week placebo-controlled period followed by a 6-week open-label period. The primary efficacy endpoint was the percentage of subjects achieving a 20% improvement in assessment in ankylosing spondylitis (ASAS)(ASAS 20). The secondary efficacy endpoints …